 "oxford, vaccine trials, coronavirus, covid-19")
The AstraZeneca-Oxford vaccine candidate has shown positive results in an interim analysis of clinical trials in the UK and Brazil, with a vaccine efficacy of up to 90 per cent in different dosing regimens.
Data from the global trials would be submitted to the Indian regulator by the end of December, and Serum Institute of India (SII), AstraZeneca’s manufacturing partner here, would submit the interim data from the Indian arm by then, sources said.
“It is up to the Indian regulator to decide which dosage form it would approve for the Indian population. Data from all the dosage forms will be presented
